This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment

Alkermes (ALKS - Get Report) will seek U.S. regulatory approval in the third quarter for a once-monthly injectable schizophrenia drug based on positive late-stage study results announced Tuesday. 

If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otsuka and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year. 

Alkermes is best known for its drug delivery technologies licensed to other companies in exchange for royalty payments. The company views aripiprazole lauroxil as a "blockbuster opportunity" so will sell the drug with its own salesforce. It's fair to say the positive results announced Tuesday are a watershed moment for Alkermes and its long-stated strategy to grow profits by selling its own drugs. Helping Alkermes along is the favorable tax structure which comes from being headquartered in Ireland.

In the phase III study, schizophrenia patients treated for 12 weeks with two different doses of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in a behavioral response scores known as Positive and Negative Syndrome Scale (PANSS) compared to placebo. Data from this study will form the basis for an approval filing with the FDA. Alkermes will need to conduct a separate study comparing aripiprazole lauroxil to another currently approved schizophrenia drug in order to seek European approval. 

Investors generally expected positive results from the aripiprazole lauroxil phase III study. Alkermes shares were up 8% to $44.57 in pre-market trading. 

J.P. Morgan analyst Cory Kasimov forecasts aripiprazole lauroxil peak sales of roughly $1 billion worldwide. Current worldwide sales of long-acting injectable drugs for schizophrenia total about $4 billion.

Abilify Maintena, approved in February 2013 and sold by Otsuka and Lundbeck, has already captured about 6.5% market share in the U.S., says Kasimov, which bodes well for Alkermes' commercial opportunity because aripiprazole lauroxil will be sold with a more convenient pre-filled syringe and multiple doses. 

Alkermes earns royalty payments based on sales of currently approved long-acting antipsychotics sold by Johnson & Johnson (JNJ - Get Report).

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs